CoAxia Announces Approval of Treatment for Cerebral Vasospasm

CoAxia, of Maple Grove, Minn., announced the HDE approval of its new NeuroFlo dual balloon, aortic catheter for the treatment of cerebral ischemia in acute vasospasm. NeuroFlo represents the first interventional device approved for use as a treatment for patients with cerebral vasospasm following repair of an aneurysmal subarachnoid hemorrhage. The HDE approval by the FDA allows treatment of up to 4,000 patients per year.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-13-2005/0003389671&EDATE=)